

EUROPEAN
CANCER
PATIENT
COALITION

Improving cancer care
Patient Perspective on value & access

Ken Mastris, Board Member of the European Cancer Patient Coalition

@cancereu

To be meaningful for patients, innovation should aim to:



- ❖ Promote patient-centred, multidisciplinary care that makes optimal use of all therapeutic modalities
- ❖ Improve upon existing care, improving quality of life as well as extending life
- ❖ Reduce inequalities in care.

Main systemic barriers

- **Low health expenditure on cancer:**
 - Cancer is the #1 killer in 17/28 EU Member States
 - 19% of overall disease burden in Europe
 - *Only 4-6% of health budgets is allocated to cancer*
- **Lack of enabling environments**
 - Lack of dialogue patient/ health professionals = suboptimal relations at hospital level = innovation does not target patients' needs
- **Limited patient involvement in decision making**
 - At all levels



Improving access to innovative medicines: Development of new drugs


- **Clinical trials**
 - European Commission & industry should support the creation of a patient-friendly European clinical trials database
- **Fast-track approvals**
 - European Commission should promote fast track approvals, but: more transparency needed on the criteria
- **Transparency Directive**
 - European Commission should tighten implementation of 180-day time limit for Member States to implement pricing and reimbursement decisions
- Patients should routinely involved in R&D (IMI-PREFER)
- Quality of Life must be integrated as endpoint in all phase 2 & 3 trials



HTA and Access to Innovative Medicines



- Health Technology Assessment can be instrumental in promoting innovation that delivers **better outcomes for patients** and society, and as a tool to ensure faster access, **measuring what matters to patients**
- HTA is **not a purely technical process**: includes economic, ethical, political & societal aspects
- It is necessary to **embed patients in all levels of HTA**
- Delays in access can result in **disease progression, reduced quality of life and distress** for the patient and carers, and potential additional cost to the healthcare system.
- Regulatory, HTA and payer decision-making processes need to evolve, recognising the need for **patient-focussed assessments of benefit**, including Quality of Life, consideration of surrogate endpoints, comprehensive patient involvement, appropriate data monitoring to confirm expected benefits, and with accountability for timelines.



EUROPEAN
CANCER
PATIENT
COALITION

Thank you!

@cancereu

ecpc.org